Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial
Abemaciclib + fulvestrant significantly improved PFS after disease progression on previous CDK4/6i + ET in patients with HR+, HER2- ABC, offering an additional targeted therapy option for these patients.
Authors
- Erika Hamilton (ORCID: https://orcid.org/0000-0002-1911-0336)
- Jiun‐I Lai (ORCID: https://orcid.org/0000-0002-8233-5466)
- Sarah Sammons (ORCID: https://orcid.org/0000-0003-2589-9422)
- Peter A. Kaufman (ORCID: https://orcid.org/0000-0003-3677-6807)
- Bastien Nguyen (ORCID: https://orcid.org/0000-0002-6166-4746)
- Holly Knoderer (ORCID: https://orcid.org/0009-0000-6373-1597)
- Seth A. Wander (ORCID: https://orcid.org/0000-0002-4127-4708)
- Yanhong Zhou (ORCID: https://orcid.org/0000-0003-2744-2100)
- Aarti Chawla
- Giampaolo Bianchini (ORCID: https://orcid.org/0000-0002-6790-6267)
- Rinath M. Jeselsohn (ORCID: https://orcid.org/0000-0001-7996-7529)
- Kevin Kalinsky (ORCID: https://orcid.org/0000-0002-3113-7902)
- Stephanie L. Graff (ORCID: https://orcid.org/0000-0003-1928-1722)
- Rachel M. Layman (ORCID: https://orcid.org/0000-0002-8663-0331)
- Sara A. Hurvitz (ORCID: https://orcid.org/0000-0001-7808-7191)
- Lacey M. Litchfield (ORCID: https://orcid.org/0009-0004-5232-9585)
- Elizabeth E. Ravenberg (ORCID: https://orcid.org/0009-0001-3972-1118)
- Montserrat Muñoz-Mateu (ORCID: https://orcid.org/0000-0001-7772-1437)
- Lillian M. Smyth (ORCID: https://orcid.org/0000-0002-0986-9285)
- Miguel Martín (ORCID: https://orcid.org/0000-0001-9237-3231)
- Cynthia Sandoval
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Harvard University (US)
- Emory University (US)
- Vita-Salute San Raffaele University (IT)
- Eli Lilly (United States) (US)
- University of Washington (US)
- Brown University (US)
- Korea University Medical Center (KR)
- University of Vermont Medical Center (US)
- Taipei Veterans General Hospital (TW)
- Hospital General Universitario Gregorio Marañón (ES)
- Massachusetts General Hospital (US)
- Fred Hutch Cancer Center (US)
- Memorial Ankara Hospital (TR)
- Sarah Cannon (US)
- Dana-Farber Cancer Institute (US)
- IRCCS Ospedale San Raffaele (IT)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2024-12-18
- DOI
- https://doi.org/10.1200/jco-24-02086
- Citations
- 44
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 18.43
Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Les Laboratories Pierre Fabre
- Puma Biotechnology
- Seagen
- Daiichi-Sankyo
- Genentech
- Daiichi Sankyo Europe